skip to main content

DOE PAGESDOE PAGES

This content will become publicly available on December 28, 2018

Title: COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin

Cisplatin-based therapy is highly toxic, but moderately effective in most cancers. Concurrent inhibition of cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH) results in antitumor activity and has organ-protective effects. The goal of this paper was to determine the antitumor activity of PTUPB, an orally bioavailable COX-2/sEH dual inhibitor, in combination with cisplatin and gemcitabine (GC) therapy. NSG mice bearing bladder cancer patient-derived xenografts were treated with vehicle, PTUPB, cisplatin, GC, or combinations thereof. Mouse experiments were performed with two different PDX models. PTUPB potentiated cisplatin and GC therapy, resulting in significantly reduced tumor growth and prolonged survival. PTUPB plus cisplatin was no more toxic than cisplatin single-agent treatment as assessed by body weight, histochemical staining of major organs, blood counts, and chemistry. The combination of PTUPB and cisplatin increased apoptosis and decreased phosphorylation in the MAPK/ERK and PI3K/AKT/mTOR pathways compared with controls. PTUPB treatment did not alter platinum–DNA adduct levels, which is the most critical step in platinum-induced cell death. The in vitro study using the combination index method showed modest synergy between PTUPB and platinum agents only in 5637 cell line among several cell lines examined. However, PTUPB is very active in vivo by inhibiting angiogenesis. Finally, PTUPB potentiatedmore » the antitumor activity of cisplatin-based treatment without increasing toxicity in vivo and has potential for further development as a combination chemotherapy partner.« less
Authors:
 [1] ;  [2] ;  [3] ;  [4] ;  [2] ;  [5] ;  [5] ;  [2] ;  [2] ;  [6] ;  [6] ;  [2] ;  [7] ;  [5] ;  [8] ;  [9] ;  [10]
  1. Univ. of California Davis, Sacramento, CA (United States). Dept. of Internal Medicine. School of Medicine; Fourth Military Medical Univ., Xi'an (China). Dept. of Urology. Xijing Hospital
  2. Univ. of California Davis, Sacramento, CA (United States). Dept. of Internal Medicine. School of Medicine
  3. Univ. of California Davis, Sacramento, CA (United States). Dept. of Biochemistry and Molecular Medicine. School of Medicine
  4. Univ. of California Davis, Sacramento, CA (United States). Dept. of Internal Medicine. School of Medicine; Wuhan Univ. (China). Dept. of Urology. Renmin Hospital
  5. Univ. of California, Davis, CA (United States). Dept. of Entomology and Nematology
  6. Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
  7. The Jackson Lab., Bar Harbor, ME (United States)
  8. Fourth Military Medical Univ., Xi'an (China). Dept. of Urology. Xijing Hospital
  9. Univ. of California Davis, Sacramento, CA (United States). Dept. of Urology. School of Medicine. Comprehensive Cancer Center
  10. Univ. of California Davis, Sacramento, CA (United States). Dept. of Internal Medicine. Dept. of Urology. School of Medicine. Comprehensive Cancer Center; VA Northern California Health Care System, Rancho Cordova, CA (United States)
Publication Date:
Report Number(s):
LLNL-JRNL-741222
Journal ID: ISSN 1535-7163
Grant/Contract Number:
AC52-07NA27344; I01 BX001784; 2 P30 CA 0933730; R01 ES002710; P42 ES04699; HHSN261201200048C; R01 DK103616; U54 NS079202
Type:
Accepted Manuscript
Journal Name:
Molecular Cancer Therapeutics
Additional Journal Information:
Journal Volume: 17; Journal Issue: 2; Journal ID: ISSN 1535-7163
Research Org:
Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States); Univ. of California Davis, Sacramento, CA (United States)
Sponsoring Org:
USDOE; Dept. of Veterans Affairs (VA) (United States); National Inst. of Health (NIH) (United States)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES
OSTI Identifier:
1438685